Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report

MLA

Yoshinari Endo, Md, et al. “Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report.” JTO Clinical and Research Reports, vol. 3, no. 1, Jan. 2022. EBSCOhost, https://doi.org/10.1016/j.jtocrr.2021.100263.

APA

Yoshinari Endo, M., Yusuke Inoue, M., PhD, Masato Karayama, M., PhD, Yasuyuki Nagata, M., PhD, Hironao Hozumi, M., PhD, Yuzo Suzuki, M., PhD, Kazuki Furuhashi, M., PhD, Noriyuki Enomoto, M., PhD, Tomoyuki Fujisawa, M., PhD, Yutaro Nakamura, M., PhD, Naoki Inui, M., PhD, & Takafumi Suda, M., PhD. (2022). Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report. JTO Clinical and Research Reports, 3(1). https://doi.org/10.1016/j.jtocrr.2021.100263

Chicago

Yoshinari Endo, Md, Md Yusuke Inoue PhD, Md Masato Karayama PhD, Md. Yasuyuki Nagata PhD, Md Hironao Hozumi PhD, Md Yuzo Suzuki PhD, Md Kazuki Furuhashi PhD, et al. 2022. “Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report.” JTO Clinical and Research Reports 3 (1). doi:10.1016/j.jtocrr.2021.100263.